J Pharm Pharmacogn Res 3(suppl. 1): S18, 2015
Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015 September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.
OC-57: HYPOLIPIDEMIC EFFECTS OF CHITOSAN AND CHITOSAN ACIDS SALTS ON TWO MODELS OF INDUCED HYPERLIPIDEMIA IN MICE
Menéndez AB1, Menéndez R1, Valle1, Phuong DT2, Phuong TN2, de la Paz N1, López O1, Fernández M3, Nogueira A1.
Introduction: Hyperlipidemia is currently considered to be one of the most important cardio-cerebral vascular disease risk factors. Cardiovascular disease is the main cause of death in developed countries; it is now widely recognized to be closely related with elevated blood lipids. Lipids mainly refer to the serum cholesterol and triglycerides. Hyperlipidemia refers to either or both of increasing levels of cholesterol or triglyceride. The purpose of this study was to determine the effect of chitosan obtained by deacetylation of chitin from lobster (Panurilus argus) shells and its salts on prevention of hyperlipidemia in mice induced by Triton WR 1339 and fed high cholesterol diets. Material and Methods: Hyperlipidemic Swiss mice were treated with chitosan and its acetate and lactate salts at dose of 200 mg/kg. Fenofibrate and colestyramine were used as positive control. Results and Conclusions: Chitosan and its acids salts caused a significant decrease in total cholesterol (TC) and tryglicerides in serum compared with control group and had an inhibition for above 50%. The data generated by this study demonstrated that chitosan and its acids salts at 200 mg/kg dose are effective in lowering the hyperlipidemia conditions produced by Triton and high cholesterol diet in mice.
Citation Format: Menéndez AB, Menéndez R, Valle, Phuong DT, Phuong TN, de la Paz N, López O, Fernández M, Nogueira A (2015) Hypolipidemic effects of chitosan and chitosan acids salts on two models of induced hyperlipidemia in mice. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S18. Abstract nr OC-57.